Down-regulation of androgen-receptor and PSA by phytochemicals

International Journal of Oncology

Volumn 32, Issue 2, 2008, Pages 405-411

  Chen, Sophie ^a,b   Gao, Jian ^a   Halicka, H Dorota ^a   Traganos, Frank ^a   Darzynkiewicz, Zbigniew ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Androgen receptor; Antiproliferation; Apoptosis; Cell cycle; Hormone refractory prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN RECEPTOR; DENDRANTHERMA MORIFOLIUM EXTRACT; GANODERMA LUCIDUM EXTRACT; GINSENG EXTRACT; GLYCYRRHIZA URALENSIS EXTRACT; ISATIS INDIGOTICA EXTRACT; ISOLIQUIRITIGENIN; ORIDONIN; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; PROSTATE SPECIFIC ANTIGEN; RABDOSIA RUBESCENS EXTRACT; SABAL EXTRACT; SCUTELLARIA BAICALENSIS EXTRACT; UNCLASSIFIED DRUG; WOGONIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENDRANTHERMA MORIFOLIUM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; ISATIS; ISATIS INDIGOTICA; MALE; MEDICINAL PLANT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; RABDOSIA; RABDOSIA RUBESCENS; RECEPTOR DOWN REGULATION;

EID: 38849098349     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.2.405     Document Type: Article

References (61)

1. American Cancer Society. Cancer Facts Figures 56: 106-130, 2006.
2. Isaacs J and Isaacs WB: Androgen receptor outwits prostate cancer drugs. Nat Mexi 10: 26-27, 2004.
3. Edwards J and Bartlett JM: The androgen receptor and signaltransduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 95: 1327-1335, 2005.
4. Quayle SN, Mawji NR, Wang J and Sadar MD: Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci USA 104: 1331-1336, 2007.
5. Hendriksen PJ, Dits NF, Kokame K, et al: Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66: 5012-2020, 2006.
6. Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Taylor CR, Datar R and Cote RJ: Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int 97: 170-178, 2006.
7. Sato M, Johnson M, Zhang L, Gambhir SS, Carey M and Wu L: Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin Cancer Res 11: 3743-3749, 2005.
8. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC and Loda M: Induction and activation of Her-2/neu occurs in an androgen-depleted envi-ronment or as a result of AR inactivation, promoting ablation-resistant survival of prostate cancer cells. Cancer Res 66: 5723-5728, 2006.
9. Disto SJ, Ma AH, Tepper CG, Chen HW and Kung HJ: Inappropriate activation of the androgen receptor by non-steroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Res 66: 10449-10459, 2006.
10. Dehm SM and Tindall DJ: Ligand-independent androgen receptor activity is activation function-2 independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem 281: 27882-27893, 2006.
11. Chen CD, Welsbie DS, Tran C, et al: Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39, 2004.
12. Kasper S and Cookson MS: Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 33: 201-210, 2006.
13. Taplin ME: Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4: 236-244, 2007.
14. Scher HI and Sawyers CL: Biology of progressive, castrationresistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261, 2005.
15. Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN and Wu J: Chemical ablation of androgen receptor in prostate cancer cells by the historie deacetylase inhibitor LAQ824. Mol Cancer Ther 4: 1311-1319, 2005.
16. Di Paola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, Zhu BT, Spaulding H, Goodin S, Toledano MB, Hait WN and Gallo MA: Clinical and biological activity of an estrogenic herbal combination (PC SPES) in prostate cancer. N Engl J Med 339: 785-791, 1998.
17. De la Tallie A, Hayek OR, Buttyan R, Bagiella E, Burchardt M and Katz AE: Effects of PC-SPES in prostate cancer: a preliminary investigation on human cell lines and patients. Br J Urol Int 84: 845-850, 1999.
18. Kubota T, Hisatake J, Hisatake Y, Said JW, Chen SS, Holden S, Taguchi H and Koeffler HP: PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. Prostate 42: 163-171, 2000.
19. Small EJ, Frahlich RB, Shinihara K, Grossfeld G, Rozenblat Z, Kevin Kelly W, Carry M and Reese DM: Perspective trial of the herbal supplement PC SPES in patients with progressive prostate cancer. J Clin Oncol 18: 3595-3603, 2000.
20. Oh WK, George DJ, Hackmann K, Manola J and Kantoff PH: Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 57: 122-126, 2001.
21. Bonham MJ, Galkin A, Montgomery B, Stahl WL, Agus D and Nelson PS: Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst 94: 1641-1647, 2002.
22. Marks LS, Di Paola RS, Nelson P, Chen S, Heber D, Belldegrun AS, Lowe FC, Fan J, Leaders FE Jr, Pantuck AJ and Tyler VE: PC-SPES: herbal formulation for prostate cancer. Urology 60: 369-375, 2002.
23. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, Di Paola RS and Small EJ: Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 22: 3705-3712, 2004.
24. Wadsworth T, Poonyagariyagorn H, Sullivan E, Koop D and Roselli CE: In vivo effect of PC-SPES on prostate growth and hepatic CYP3A expression in rats. J Pharmacol Exp Ther 306: 187-194, 2003.
25. Walsh PC: American Society of Clinical Oncology recommendations for the initial hormonal management of androgensensitive metastatic, recurrent or progressive prostate cancer. J Urol 173: 1966, 2005.
26. Hsieh TC, Chen SS, Wang X and Wu JM: Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem Mol Biol Int 42: 535-544, 1997.
27. Chen S, Ruan Q, Bedner E, Deptala A, Wang X, Hsieh TC, Traganos F and Darzynkiewicz Z: Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Prolif 34: 293-304, 2001.
28. Ikezoe T, Chen SS, Heber D, Taguchi H and Koeffler HP: Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 49: 285-292, 2001.
29. Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H and Koeffier HP: Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 23: 1187-1193, 2003.
30. Chen S, Gao J, Halicka HD, Huang X, Traganos F and Darzynkiewicz Z: The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol 26: 579-588, 2005.
31. Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, Bubley GJ, Lu ML and Balk SP: Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathology 169: 682-696, 2006.
32. Darzynkiewicz Z, Traganos F, Wu JM and Chen S: Chinese herbal mixture PC SPES in treatment of prostate cancer. (Review). Int J Oncol 7: 729-736, 2000.
33. Chen S: In vitro mechanism of PC SPES. Urology 58 (Suppl 1): 28-35, 2001.
34. Queires LC, Fauvel-Lafetve F, Terry S, De la Taille A, Kouyoumdjian JC, Chopin DK, Vacherot F, Rodrigues LE and Crepin M: Polyphenols purified from the Brazilian aroeira plant (Schinus terebinthifolius, Raddi) induce apoptotic and autophagic cell death of DU145 cells. Anticancer Res 26: 379-387, 2006.
35. Sanchez AM, Sanchez MG, Malagarie-Cazenave S, Olea N and Diaz-Laviada I: Capsaicin, the pungent ingredient of hot chilli pepper, has been recently shown to induce apoptosis in PC-3 via activation of caspase 3. Apoptosis 11: 89-99, 2006.
36. Liu JJ, Huang RW, Lin D J, Wu XY, Peng J, Pari XL, Lin Q, Hou M, Zhang MH and Chen F: Antiproliferation effects of oridonin on HPB-ALL cells and its mechanisms of action. Am J Hematol 81: 86-94, 2006.
37. Zhang JF, Liu JJ, Liu PQ, Lin DJ, Li XD and Chen GH: Oridonin can inhibit cell growth by induction of apoptosis in BEL-7402 cells via activation of caspase-3 as well as downregulation of Bel-2 and up-regulation of Bax expression. Hepatol Res 35: 104-110, 2006.
38. Ma Z, Otsuyama K, Liu S, Abroun S, Ishikawa H, Tsuyama N, Obata M, Li FJ, Zheng X, Maki Y, Miyamoto K and Kawano MM: Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 105: 3312-3318, 2005.
39. Park EJ, Zhao YZ, Lian L, Kim YC and Sohn DH: Wogonin in S. baicalensis selectively induced apoptosis in T-HSC/CI-6 cells via caspase-3 and caspase-9 activation. Plant Med 71: 885-887, 2005.
40. Chen YC, Shen SC, Lee WR, Lin HY, Ko CH, Shih CM and Yang LL: Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol 76: 351-359, 2002.
41. Jung JI, Lira SS, Choi HJ, Cho HJ, Shin HK, Kim EJ, Chung WY, Park KK and Park JH: Isoliquritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells. J Nutr Biochem 17: 89-96, 2006.
42. Ikezoe T, Yang Y, Bandobashi K, Salto T, Takemoto S, Machida H, Togitani K, Koeffler HP and Taguchi H: Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 4: 578-586, 2005.
43. Tang NY, Yang JS, Chang YH, Lu HF, Hsia TC, Lin WC and Chung JG: Effects of wogonin on the levels of cytokines and functions of leukocytes associated with NF-kappa B expression in Sprague-Dawley rats. in Vivo 20: 527-532, 2006.
44. Lee SO, Jeong YJ, Yu MH, Lee JW, Hwangbo MH, Kim CH and Lee IS: Wogonin suppresses TNF-alpha-induced MMP-9 expression by blocking the NF-kappaB activation via MAPK signaling pathways in human aortic smooth muscle cells. Biochem Biophys Res Commun 351: 118-125, 2006.
45. Kwon HM, Choi YJ, Choi JS, Kang SW, Bae JY, Kang IJ, Jun JG, Lee SS, Lim SS and Kang YH: Blockade of cytokineinduced endothelial cell adhesion molecule expression by licorice isoliquiritigenin through NF-kappaB signal disruption. Exp Biol Med 232: 235-245, 2007.
46. Suh J and Rabson AB: NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 91: 100-117, 2004.
47. Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S and Sarkar FH: Down-regulation of androgen receptor by 3,3'diindolylmethane contributes to imhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 66: 10064-10072, 2006.
48. Lee SO, Lou W, Nadiminty N, Lin X and Gao AC: Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 64: 160-167, 2005.
49. Zerbini LF, Wang Y, Cho JY and Libermann TA: Constitutive activation of nuclear factor B p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63: 2206-2215, 2003.
50. Armstrong K, Robson CN and Leung HY: NF-kappaB activation up-regulates fibroblast growth factor 8 expression in prostate cancer cells. Prostate 66: 1223-1234, 2006.
51. Peant B, Diallo JS, Lessard L, Delvoye N, Le Page C, Saad F and Mes-Masson AM: Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factorkappaB transcription factor in prostate cancer. Mol Cancer Res 5: 87-94, 2007.
52. Narayanan BA, Narayanan NK, Pittman B and Reddy BS: Regression of mouse prostatic intraepithelial neoplasia by non-steroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate M. Clin Cancer Res 10: 7727-7737, 2004.
53. Narayanan BA, Narayanan NK, Davis L and Nargi D: RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth. Mol Cancer Ther 5: 1117-1125, 2006.
54. Hughes-Fulford M, Li CF, Boonyaratanakornkit J and Sayyah S: Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res 66: 1427-1433, 2006.
55. Asirvatham AJ, Schmidt M, Gao B and Chaudhary J: Androgens regulate the immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells. Endocrinology 147: 257-271, 2005.
56. Cohen BL, Gomez P, Omori Y, et al: Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 119: 1082-1087, 2006,
57. Mahmud SM, Tanguay S, Begin LR, Franco EL and Aprikian AG: Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 15: 158-164, 2006.
58. Miyamoto H, Altuwaijri S, Cai Y, Messing EM and Chang C: Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog 44: 1-10, 2005.
59. Thelen P, Peter T, Hunermund A, et al: Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cells. BJU lnt 100: 199-203, 2007.
60. Arnold JT, Liu X, Allen JD, Le H, McFann KK and Blackman MR: Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate 67: 1152-1162, 2007.
61. Mostaghel EA, Page ST, Lin DW, et al: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67: 5033-5041, 2007.